Claims
- 1. A method for delaying the decrease in collagen inherent in naturally-aged (chronologically-aged) human skin, comprising: providing a composition including a non-toxic amount of retinoid in a cosmetically suitable vehicle and applying said composition to the skin on a regular basis in an amount effective to delay both the decrease in procollagen biosynthesis and the increase in enzymatic collagen degradation inherent in naturally-aged human skin.
- 2. The method of claim 1, wherein the skin is sun-protected skin.
- 3. The method of claim 1, wherein the retinoid is selected from retinol, retinal, retinoic acid, a retinoic acid salt, a derivative or analog thereof, or a mixture thereof.
- 4. The method of claim 3, wherein the retinoid is retinol or a mixture of retinol and retinoic acid.
- 5. The method of claim 1, wherein the retinoid is applied daily.
- 6. The method of claim 1, further comprising the topical administration of an effective, non-toxic amount of a non-retinoid MMP inhibitor.
- 7. The method of claim 6, wherein the MMP inhibitor is selected from aspirin, E5510, glucocorticoids, Vitamin D3, G112947, TIMPs, hydroxamates and hydroxy-urea derivatives, and tetracyclines and derivatives thereof, and the various salts thereof, and compatible mixtures thereof.
- 8. The method of claim 6, wherein the MMP inhibitor is selected from the group consisting of genistein, galardin, batimastat, marimastat, N-acetyl cysteine, and green tea extract.
- 9. The method of claim 6, wherein said retinoid and said MMP inhibitor are present in a single, topically administered formulation.
- 10. The method of claim 7, wherein said retinoid and said MMP inhibitor are present in a single, topically administered formulation.
- 11. The method of claim 8, wherein said retinoid and said MMP inhibitor are present in a single, topically administered formulation.
- 12. A method for delaying the increase in collagen degradation inherent in naturally-aged (chronologically-aged) human skin, comprising, providing a composition including a non-toxic amount of non-retinoid MMP inhibitor in a cosmetically-suitable vehicle and applying said composition to the skin on a regular basis in an amount effective to delay the increase in enzymatic collagen degradation inherent in naturally-aged human skin.
- 13. The method of claim 12, wherein the MMP inhibitor is selected from aspirin, E5510, glucocorticoids, Vitamin D3, GI12947, TIMPs, hydroxamates and hydroxy-urea derivatives, and tetracyclines and derivatives thereof, and the various salts thereof, and compatible mixtures thereof.
- 14. The method of claim 12, wherein the MMP inhibitor is selected from the group consisting of genistein, galardin, batimastat, marimastat, N-acetyl cysteine, and green tea extract.
- 15. The method of claim 12, further comprising the topical application, on a regular basis, of a retinoid.
- 16. The method of claim 15, wherein the topical application of the retinoid and the MMP inhibitor are concurrent.
- 17. The method of claim 15, wherein the topical application of the retinoid and the MMP inhibitor are not concurrent.
- 18. The method of claim 15, wherein the retinoid is retinoic acid, retinol, or a mixture thereof.
RELATED APPLICATIONS
[0001] This application is based on provisional applications 60/040,594, filed Feb. 25, 1997, 60/042,976, filed Apr. 7, 1997, and 60/073,214, filed Jan. 30, 1998, and is a divisional of utility application Ser. No. 09/028,435, filed Feb. 24, 1998, the disclosures of which are incorporated herein by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60040594 |
Feb 1997 |
US |
|
60042976 |
Apr 1997 |
US |
|
60073214 |
Jan 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09028435 |
Feb 1998 |
US |
Child |
10458355 |
Jun 2003 |
US |